You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

camrelizumab

Showing 1 - 25 of 155
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acral Melanoma Trial (camrelizumab+apatinib+TMZ, camrelizumab+apatinib, camrelizumab)

Not yet recruiting
  • Acral Melanoma
  • (no location specified)
Mar 16, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 24, 2023

Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Chengdu (Camrelizumab, Dalpiciclib 100mg,

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Camrelizumab
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 25, 2023

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Recruiting
  • Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Jan 4, 2023

Triple-Negative Breast Cancer Trial in Shanghai (Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 27, 2023

Immunotherapy, Chemo Trial in Guandong (Camrelizumab)

Recruiting
  • Immunotherapy
  • Chemotherapy
  • Camrelizumab
  • Guandong, Guangdong, China
    Nanfang Hospital, Southern Medical University
Apr 22, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • Camrelizumab
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023

Advanced Gastric Adenocarcinoma Trial in Henan (camrelizumab)

Recruiting
  • Advanced Gastric Adenocarcinoma
  • camrelizumab
  • Henan, China
    Henan Tumor Hospital
Oct 13, 2022

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Camrelizumab
  • +2 more
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023

Esophageal Tumors, Esophageal Diseases, Digestive System Tumors Trial (Camrelizumab, Paclitaxel, Platinum)

Not yet recruiting
  • Esophageal Neoplasms
  • +2 more
  • Camrelizumab
  • +3 more
  • (no location specified)
Nov 20, 2022

Hepatocellular Carcinoma Trial in Jinan (Camrelizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Camrelizumab
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Nov 16, 2022

Ovarian Clear Cell Carcinoma Trial (Camrelizumab)

Not yet recruiting
  • Ovarian Clear Cell Carcinoma
  • Camrelizumab
  • (no location specified)
Oct 29, 2022

Second Line Treatment of Gastric Cancer Trial (Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan)

Not yet recruiting
  • Second Line Treatment of Gastric Cancer
  • Camrelizumab
  • +2 more
  • (no location specified)
Dec 20, 2022

Adrenocortical Carcinoma Trial (Camrelizumab)

Recruiting
  • Adrenocortical Carcinoma
  • Camrelizumab
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Dec 16, 2022

Hepatocellular Carcinoma, Immunotherapy, Preoperative Trial in Nanjing (Camrelizumab, Apatinib Mesylate, Postoperative TACE

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Camrelizumab
  • +4 more
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
Nov 6, 2022

Multicenter, Prospective, Real World Study of Camrelizumab in

Not yet recruiting
  • NSCLC
  • Camrelizumab
  • (no location specified)
Sep 19, 2022

Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Brain Metastases
  • Camrelizumab
  • +2 more
  • Guangzhou, Guangzhou, China
    Li-Kun Chen
Nov 13, 2022

Melanoma, Acral Melanoma, Temozolomide Trial (Camrelizumab)

Not yet recruiting
  • Melanoma
  • +6 more
  • Camrelizumab
  • (no location specified)
Aug 21, 2022

Hepatocellular Carcinoma Trial in Nanjing (Camrelizumab, TACE, Apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Camrelizumab
  • +2 more
  • Nanjing, Jiangsu, China
    Zhongda Hospital
Sep 8, 2022

Stomach Tumors, Digestive System Tumors, Tumors Trial in Fuzhou (Camrelizumab, SOX, Surgery)

Active, not recruiting
  • Stomach Neoplasms
  • +5 more
  • Camrelizumab
  • +2 more
  • Fuzhou, Fujian, China
    The Second Affiliated Hospital of Fujian Medical University
Nov 1, 2022

Nasopharyngeal Carcinoma Trial in Shanghai (Camrelizumab, Nimotuzumab, neoadjuvant chemo and CCRT)

Recruiting
  • Nasopharyngeal Carcinoma
  • Camrelizumab
  • +2 more
  • Shanghai, Shanghai, China
    Fudan Universtiy Shanghai Cancer Centre
Mar 6, 2023

Esophageal Carcinoma Trial in Tianjin (camrelizumab)

Recruiting
  • Esophageal Carcinoma
  • camrelizumab
  • Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Jul 25, 2022

Squamous Cell Carcinoma of the Skin Trial in Zhengzhou (Camrelizumab)

Not yet recruiting
  • Squamous Cell Carcinoma of the Skin
  • Camrelizumab
  • Zhengzhou, Henan, China
    Department of Bone and Soft Tissue ,Henan Cancer Hospital
Aug 3, 2022

Breast Cancer Trial in Nanjing (Microwave Ablation, Camrelizumab, Breast Surgery)

Recruiting
  • Breast Cancer
  • Microwave Ablation
  • +2 more
  • Nanjing, Jiangsu, China
    the First Affiliated Hospital of Nanjing Medical University
Jul 19, 2022

NSCLC Metastatic Trial in Chengdu (Camrelizumab, stereotactic body radiation therapy, Chemotherapy)

Recruiting
  • Non-small Cell Lung Cancer Metastatic
  • Camrelizumab
  • +2 more
  • Chengdu, Sichuan, China
    Sichuan Cancer Hospital & Institute
Jul 21, 2022